InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.02
(
-0.13%
)
Bitcoin
66,565.58
(
-0.11%
)
Post# of 252209
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

randychub

Send PM Follow Ignore
Followers 26
Posts 2584
Boards Moderated 0
Alias Born 10/23/2003

randychub

Re: None

Tuesday, 09/20/2005 8:35:08 AM

Tuesday, September 20, 2005 8:35:08 AM

Post# of 252209
Sept. 20, 2005--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that it has entered into an agreement for further production of MM-093 for Merrimack Pharmaceuticals, Inc. MM-093, Merrimack's lead clinical product, is a recombinant version of human alpha-fetoprotein. Merrimack is conducting a Phase II study of MM-093 in patients with rheumatoid arthritis and is planning additional clinical studies.
ADVERTISEMENT

http://biz.yahoo.com/bw/050920/205337.html?.v=1

"We are pleased to continue to support Merrimack's supply needs for their clinical studies of MM-093," stated Gregory Liposky, GTC's Senior Vice President of Operations. "GTC's technology is a cost-effective production method for recombinant proteins and is well suited for the production of Merrimack's human alpha-fetoprotein."

About Merrimack Pharmaceuticals

Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. Its lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid arthritis. MM-093 is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics.

Merrimack is a privately held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up